Skip to main content
Top
Published in: Diabetologia 7/2009

01-07-2009 | Article

The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men

Authors: K. Pilgaard, C. B. Jensen, J. H. Schou, V. Lyssenko, L. Wegner, C. Brøns, T. Vilsbøll, T. Hansen, S. Madsbad, J. J. Holst, A. Vølund, P. Poulsen, L. Groop, O. Pedersen, A. A. Vaag

Published in: Diabetologia | Issue 7/2009

Login to get access

Abstract

Aims/hypothesis

We studied the physiological, metabolic and hormonal mechanisms underlying the elevated risk of type 2 diabetes in carriers of TCF7L2 gene.

Methods

We undertook genotyping of 81 healthy young Danish men for rs7903146 of TCF7L2 and carried out various beta cell tests including: 24 h glucose, insulin and glucagon profiles; OGTT; mixed meal test; IVGTT; hyperglycaemic clamp with co-infusion of glucagon-like peptide (GLP)-1 or glucose-dependent insulinotropic polypeptide (GIP); and a euglycaemic–hyperinsulinaemic clamp combined with glucose tracer infusion to study hepatic and peripheral insulin action.

Results

Carriers of the T allele were characterised by reduced 24 h insulin concentrations (p < 0.05) and reduced insulin secretion relative to glucose during a mixed meal test (beta index: p < 0.003), but not during an IVGTT. This was further supported by reduced late-phase insulinotropic action of GLP-1 (p = 0.03) and GIP (p = 0.07) during a 7 mmol/l hyperglycaemic clamp. Secretion of GLP-1 and GIP during the mixed meal test was normal. Despite elevated hepatic glucose production, carriers of the T allele had significantly reduced 24 h glucagon concentrations (p < 0.02) suggesting altered alpha cell function.

Conclusions/interpretation

Elevated hepatic glucose production and reduced insulinotropic effect of incretin hormones contribute to an increased risk of type 2 diabetes in carriers of the rs7903146 risk T allele of TCF7L2.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chandak GR, Janipalli CS, Bhaskar S et al (2007) Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 50:63–67PubMedCrossRef Chandak GR, Janipalli CS, Bhaskar S et al (2007) Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 50:63–67PubMedCrossRef
2.
go back to reference Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250PubMedCrossRef Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250PubMedCrossRef
3.
go back to reference Grant SFA, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef Grant SFA, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef
4.
go back to reference Helgason A, Palsson S, Thorleifsson G et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225PubMedCrossRef Helgason A, Palsson S, Thorleifsson G et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225PubMedCrossRef
5.
go back to reference Horikoshi M, Hara K, Ito C, Nagai R, Froguel P, Kadowaki T (2007) A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 50:747–751PubMedCrossRef Horikoshi M, Hara K, Ito C, Nagai R, Froguel P, Kadowaki T (2007) A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 50:747–751PubMedCrossRef
6.
go back to reference Mayans S, Lackovic K, Lindgren P et al (2007) TCF7L2 polymorphisms are associated with type 2 diabetes in northern Sweden. Eur J Hum Genet 15:342–346PubMedCrossRef Mayans S, Lackovic K, Lindgren P et al (2007) TCF7L2 polymorphisms are associated with type 2 diabetes in northern Sweden. Eur J Hum Genet 15:342–346PubMedCrossRef
7.
go back to reference van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A et al (2007) Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 50:59–62PubMedCrossRef van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A et al (2007) Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 50:59–62PubMedCrossRef
8.
go back to reference Zhang CL, Qi L, Hunter DJ et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of US women and men. Diabetes 55:2645–2648PubMedCrossRef Zhang CL, Qi L, Hunter DJ et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of US women and men. Diabetes 55:2645–2648PubMedCrossRef
9.
go back to reference Cauchi S, El AY, Choquet H et al (2007) TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med (Berlin) 85:777–782 Cauchi S, El AY, Choquet H et al (2007) TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med (Berlin) 85:777–782
10.
go back to reference Loos RJF, Franks PW, Francis RW et al (2007) TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 56:1943–1947PubMedCrossRef Loos RJF, Franks PW, Francis RW et al (2007) TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 56:1943–1947PubMedCrossRef
11.
go back to reference Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef
12.
go back to reference Schäfer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443–2450PubMedCrossRef Schäfer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443–2450PubMedCrossRef
13.
go back to reference Nauck MA, Meier JJ (2007) The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. Diabetologia 50:2413–2416PubMedCrossRef Nauck MA, Meier JJ (2007) The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. Diabetologia 50:2413–2416PubMedCrossRef
14.
go back to reference Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464PubMedCrossRef Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464PubMedCrossRef
15.
go back to reference Unger RH (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837–848PubMedCrossRef Unger RH (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837–848PubMedCrossRef
16.
go back to reference Vaag AA, Holst JJ, Volund A, Beck-Nielsen H (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMedCrossRef Vaag AA, Holst JJ, Volund A, Beck-Nielsen H (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMedCrossRef
17.
go back to reference Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide-1 (7-36-amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307PubMedCrossRef Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide-1 (7-36-amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307PubMedCrossRef
18.
go back to reference Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111–1119PubMedCrossRef Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111–1119PubMedCrossRef
19.
go back to reference Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA (2002) Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 51:1271–1280PubMedCrossRef Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA (2002) Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 51:1271–1280PubMedCrossRef
20.
go back to reference Schou JH, Pilgaard K, Vilsbøll T et al (2005) Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. J Clin Endocrinol Metab 90:4912–4919PubMedCrossRef Schou JH, Pilgaard K, Vilsbøll T et al (2005) Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. J Clin Endocrinol Metab 90:4912–4919PubMedCrossRef
21.
go back to reference Freathy RM, Weedon MN, Bennett A et al (2007) Type 2 diabetes TCF7L2 risk genotypes alter birth weight: A study of 24,053 individuals. Am J Hum Genet 80:1150–1161PubMedCrossRef Freathy RM, Weedon MN, Bennett A et al (2007) Type 2 diabetes TCF7L2 risk genotypes alter birth weight: A study of 24,053 individuals. Am J Hum Genet 80:1150–1161PubMedCrossRef
22.
go back to reference Kjems LL, Roder ME, Dinesen B, Hartling SG, Jorgensen PN, Binder C (1993) Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem 39:2146–2150PubMed Kjems LL, Roder ME, Dinesen B, Hartling SG, Jorgensen PN, Binder C (1993) Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem 39:2146–2150PubMed
23.
go back to reference Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin. Biochem J 207:381–388PubMed Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin. Biochem J 207:381–388PubMed
24.
go back to reference Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA (1998) Measuring prehepatic insulin secretion using a population model of C-peptide kinetics: Accuracy and required sampling schedule. Diabetologia 41:548–554PubMedCrossRef Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA (1998) Measuring prehepatic insulin secretion using a population model of C-peptide kinetics: Accuracy and required sampling schedule. Diabetologia 41:548–554PubMedCrossRef
25.
go back to reference Kjems LL, Volund A, Madsbad S (2001) Quantification of beta-cell function during IVGTT in type II and non-diabetic subjects: Assessment of insulin secretion by mathematical methods. Diabetologia 44:1339–1348PubMedCrossRef Kjems LL, Volund A, Madsbad S (2001) Quantification of beta-cell function during IVGTT in type II and non-diabetic subjects: Assessment of insulin secretion by mathematical methods. Diabetologia 44:1339–1348PubMedCrossRef
26.
go back to reference Cauchi S, Meyre D, Dina C et al (2006) Transcription factor TCF7L2 genetic study in the French population—expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 55:2903–2908PubMedCrossRef Cauchi S, Meyre D, Dina C et al (2006) Transcription factor TCF7L2 genetic study in the French population—expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 55:2903–2908PubMedCrossRef
27.
go back to reference Loder MK, Xavier GDS, McDonald A, Rutter GA (2008) TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic β-cells. Biochem Soc Trans 36:357–359PubMedCrossRef Loder MK, Xavier GDS, McDonald A, Rutter GA (2008) TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic β-cells. Biochem Soc Trans 36:357–359PubMedCrossRef
28.
go back to reference Rulifson IC, Karnik SK, Heiser PW et al (2007) Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci USA 104:6247–6252PubMedCrossRef Rulifson IC, Karnik SK, Heiser PW et al (2007) Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci USA 104:6247–6252PubMedCrossRef
30.
go back to reference Liu ZY, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735PubMedCrossRef Liu ZY, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735PubMedCrossRef
32.
go back to reference Fehmann HC, Goke R, Goke B (1995) Cell and molecular-biology of the incretin hormones glucagon- like peptide-i and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390–410PubMed Fehmann HC, Goke R, Goke B (1995) Cell and molecular-biology of the incretin hormones glucagon- like peptide-i and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390–410PubMed
33.
go back to reference Huypens P, Ling Z, Pipeleers D, Schuit F (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43:1012–1019PubMedCrossRef Huypens P, Ling Z, Pipeleers D, Schuit F (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43:1012–1019PubMedCrossRef
34.
go back to reference Sørensen H, Winzell MS, Brand CL et al (2006) Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55:3463–3469PubMedCrossRef Sørensen H, Winzell MS, Brand CL et al (2006) Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55:3463–3469PubMedCrossRef
35.
go back to reference Wegner L, Hussain MS, Pilgaard K et al (2008) Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab 93:4013–4019PubMedCrossRef Wegner L, Hussain MS, Pilgaard K et al (2008) Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab 93:4013–4019PubMedCrossRef
36.
go back to reference Brackenridge A, Pearson ER, Shojaee-Moradie F, Hattersley AT, Russell-Jones D, Umpleby AM (2006) Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1 beta and -1 alpha mutations. Diabetes 55:405–411PubMedCrossRef Brackenridge A, Pearson ER, Shojaee-Moradie F, Hattersley AT, Russell-Jones D, Umpleby AM (2006) Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1 beta and -1 alpha mutations. Diabetes 55:405–411PubMedCrossRef
37.
go back to reference Knauf C, Cani PD, Perrin C et al (2005) Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554–3563PubMedCrossRef Knauf C, Cani PD, Perrin C et al (2005) Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554–3563PubMedCrossRef
38.
go back to reference Rouille Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases pc2 and pc3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270:26488–26496PubMedCrossRef Rouille Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases pc2 and pc3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270:26488–26496PubMedCrossRef
39.
go back to reference Rouille Y, Westermark G, Martin SK, Steiner DF (1994) Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc Natl Acad Sci USA 91:3242–3246PubMedCrossRef Rouille Y, Westermark G, Martin SK, Steiner DF (1994) Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc Natl Acad Sci USA 91:3242–3246PubMedCrossRef
Metadata
Title
The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men
Authors
K. Pilgaard
C. B. Jensen
J. H. Schou
V. Lyssenko
L. Wegner
C. Brøns
T. Vilsbøll
T. Hansen
S. Madsbad
J. J. Holst
A. Vølund
P. Poulsen
L. Groop
O. Pedersen
A. A. Vaag
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1307-x

Other articles of this Issue 7/2009

Diabetologia 7/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.